Advertisement

Lung Cancer

  • Ronald C. Walker
  • Laurie B. Jones-Jackson
  • Aaron C. Jessop
  • Dominique Delbeke
Chapter

Abstract

In 2004, an estimated 173,700 Americans were diagnosed with lung cancer; of these, about 164,440 (95%) will die of their disease. Despite decades of research, the prognosis for lung cancer remains dismal, with a 5-year survival rate of 14%. Nonetheless, benefits have been realized for most patients, mainly through improved quality of life and some prolonged survival. Importantly, lung cancer can be curable if detected in its early stages.

Keywords

Positron Emission Tomography Standardize Uptake Value Pulmonary Nodule Malignant Pleural Mesothelioma Solitary Pulmonary Nodule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Spira A, Ettinger D. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379–392.CrossRefPubMedGoogle Scholar
  2. 2.
    Ost D, Fein A, Feinsilver S. The solitary pulmonary nodule. New Engl J Med 2003; 348:2535–2542.CrossRefPubMedGoogle Scholar
  3. 3.
    Erasmus JJ, Connoly JE, McAdams HP, Roggli VL. Solitary pulmonary nodules: Part I. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics 2000;20:43–58.PubMedGoogle Scholar
  4. 4.
    Yankelevitz DF, Henschke CI. Does 2-year stability imply that pulmonary nodules are benign? AJR Am J Roentgenol 1997;168:325–328.PubMedGoogle Scholar
  5. 5.
    Zerhouni EA, Stitik FP, Siegelman SS, Naidich DP, Sagel SS, Proto AV, Muhm JR, Walsh JW, Martinez CR, Heelan RT. CT of the pulmonary nodule: a cooperative study. Radiology 1986;160:319–327.PubMedGoogle Scholar
  6. 6.
    Swensen SJ, Viggiano RW, Midthun DE, Müller NL, Sherrick A, Yamashita K, Naidich DP, Patz EF, Hartman TH, Muhm JR, Weaver AL. Lung nodule enhancement at CT: Multicenter study. Radiology 2000;214:73–80.PubMedGoogle Scholar
  7. 7.
    Conces DJ Jr, Schwenk GR Jr, Doering PR, Glant MD. Thoracic needle biopsy: Improved results utilizing a team approach. Chest 1987;91:813–816.CrossRefPubMedGoogle Scholar
  8. 8.
    Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. The international early lung cancer action program investigators. Survival of patients with stage I lung cancer detected on CT screening. New Engl J Med 2006;255:1763–1771.Google Scholar
  9. 9.
    Unger M. A pause, progress and reassessment in lung cancer screening. New Engl J Med 2006;355:1822–1824.CrossRefPubMedGoogle Scholar
  10. 10.
    Winer-Muram H. The solitary pulmonary nodule. Radiology 2006;239:34–49.CrossRefPubMedGoogle Scholar
  11. 11.
    Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, Mailliard JA, Phalen JJ, Sunderland JJ, Frick MP. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992;184:441–444.PubMedGoogle Scholar
  12. 12.
    Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA 2001;285:914–924.CrossRefPubMedGoogle Scholar
  13. 13.
    Joo Hyun O, Ie Ryung Y, Sung Hoon K, Sohn HS, Chung HK. Clinical significance of small pulmonary nodules with little or No 18 F-FDG uptake on PET/CT images of patients with nonthoracic malignancies. J Nucl Med 2007;48:15–21.Google Scholar
  14. 14.
    Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE, Emi T, Phelps ME. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113–2125.PubMedGoogle Scholar
  15. 15.
    Gould MK, Sanders GD, Barnett PG, Rydzak CE, Maclean CC, McClellan MB, Owens DK. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med 2003;138:724–735.PubMedGoogle Scholar
  16. 16.
    Matthies A, Hickeson M, Cuchiara A, Aliva A. Dual time point 18 F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871–875.PubMedGoogle Scholar
  17. 17.
    Henschke CI, Yankelevitz D, Westcott J, Davis SD, Fleishon H, Gefter WB, McLoud TC, Pugatch RD, Sostman HD, Tocino I, White CS, Bode FR, Swensen SJ. Work-up of the solitary pulmonary nodule. Radiology 2000;215:Suppl:607–609.PubMedGoogle Scholar
  18. 18.
    Mountain C. Revisions in the international system for staging lung cancer. Chest 1997;111:1710–1717.CrossRefPubMedGoogle Scholar
  19. 19.
    Birim O, Kappetein AP, Stijnen T, Bogers AJJC. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in non small cell lung cancer. Ann Thorac Surg 2005;79:375–381.CrossRefPubMedGoogle Scholar
  20. 20.
    Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza C, Detterbeck F. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd Edition). Chest 2007;132:178S–201S.CrossRefPubMedGoogle Scholar
  21. 21.
    Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. New Engl J Med 2003;348:2500–2507.CrossRefPubMedGoogle Scholar
  22. 22.
    Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: A review of the current evidence. Chest 2003;123:137S–146S.CrossRefPubMedGoogle Scholar
  23. 23.
    MacManus, MP, Hicks, RJ, Matthews, JP, Hogg A, McKenzie AF, Wirth A, Ware RE, Ball DL. High rate of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: Implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287–293.CrossRefPubMedGoogle Scholar
  24. 24.
    Ludwig V, Komori T, Kolb DC, Martin WH, Sandler MP, Delbeke D. Cerebral lesions incidentally detected on FDG PET images of patients evaluated for body malignancies. Mol Imaging Biol 2002;4:359–362.CrossRefPubMedGoogle Scholar
  25. 25.
    Boland GW, Goldberg MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MM, Mueller PR. Indeterminate adrenal masses in patients with cancer. Evaluation at PET with 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 1995;194:131–134.PubMedGoogle Scholar
  26. 26.
    Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244–1247.CrossRefPubMedGoogle Scholar
  27. 27.
    Verboom P, van Tinteren H, Hoekstra OS, Smit EF, van den Bergh J, Schreurs A, Stallaert R, Velthoven P, Comans E, Diepenhorst F, Mourik JC, Postmus PE, Boers M, Grijseels EWM, Teule GJJ, Uyl-de Groot CA, the PLUS study group. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: The PLUS study. Eur J Nucl Med Mol Imaging 2003;30:1444–1449.CrossRefPubMedGoogle Scholar
  28. 28.
    van Tinteren H, Hoekstra OS, Smit EF,van den Bergh J, Schreurs A, Stallaert R, van Velthoven P, Comans E, Diepenhorst F, Verboom P. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388–1393.CrossRefPubMedGoogle Scholar
  29. 29.
    MacManus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285–1292.CrossRefGoogle Scholar
  30. 30.
    Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, Gauler T, Antoch G, Bockisch A, Stuschke M. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in nonsmall cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006;12:97–106.CrossRefPubMedGoogle Scholar
  31. 31.
    Cerfolio RJ, Bryant AS, Buddhiwardhan O. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study. J Thorac Cardiovasc Surg 2006;131:1229–1235.CrossRefPubMedGoogle Scholar
  32. 32.
    Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Dittmann H, Langen H, Bares R. Repeat 18 F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III nonsmall cell lung cancer. Lung Cancer 2007;55:165–171.CrossRefPubMedGoogle Scholar
  33. 33.
    Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, Schwaiger M. Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651–2657.CrossRefPubMedGoogle Scholar
  34. 34.
    De Leyn P, Stoobants S, Dewever W, Lerut T, Coosemans W, Decker G, Nafteux P, Van Raemdonck D, Mortelmans L, Nackaerts K, Vansteenkiste J. Prospective comparative study of integrated positron emission tomography-computed tomography compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy proven stage IIIA-N2 nonsmall cell lung cancer: A Leuven Lung Cancer Group study. J Clin Oncol 2006;24:3333–3339.CrossRefPubMedGoogle Scholar
  35. 35.
    Hellwig D, Groschel A, Graeter TP, Hellwig AP, Nestle U, Schäfers HJ, Sybrecht GW, Kirsch CM. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:13–21.CrossRefPubMedGoogle Scholar
  36. 36.
    Green FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Handbook, sixth edition. New York: Springer, 2004.Google Scholar
  37. 37.
    Samson DJ, Seidenfeld J. Simon GR, Turrisi AT 3rd, Bonnell C, Ziegler KM, Aronson N. Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:314S–323S.CrossRefPubMedGoogle Scholar
  38. 38.
    Schumacher T, Brink I, Mix M, Reinhardt M, Herget G, Digel W, Henke M, Moser E, Nitzsche E. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001;28:483–488.CrossRefPubMedGoogle Scholar
  39. 39.
    Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18 F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med 2003;30:78–84.CrossRefGoogle Scholar
  40. 40.
    Brink I, Schumacher T, Mix M,Ruhland S,Stoelben E, Digel W,Henke M, Ghanem N, Moser E,Nitzsche EU. Impact of [18 F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1614–1620.CrossRefPubMedGoogle Scholar
  41. 41.
    Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591–1603.CrossRefPubMedGoogle Scholar
  42. 42.
    Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the international mesothelioma interest group. Lung Cancer 1996;14:1–12.CrossRefPubMedGoogle Scholar
  43. 43.
    Flores RM, Akhurst T, Gonen M, Larson S. Rusch V. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2003;126:11–15.CrossRefPubMedGoogle Scholar
  44. 44.
    Truong MT, Marom EM, Erasmus JJ. Preoperative evaluation of patients with malignant pleural mesothelioma: Role of integrated CT-PET imaging. J Thorac Imaging 2006;21:146–153.CrossRefPubMedGoogle Scholar
  45. 45.
    Wang ZJ, Reddy GP, Gotway MB, Higgins CB, Jablons DM, Ramaswamy M, Hawkins RA, Webb WR. Malignant pleural mesothelioma: Evaluation with CT, MR imaging, and PET. Radio Graphics 2004;24:105–119.CrossRefPubMedGoogle Scholar
  46. 46.
    Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, Incarbone M, Alloisio M, Santoro A. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18 F]Fluorodeoxyglucose. J Clin Oncol 2006;24:4587–4593.CrossRefPubMedGoogle Scholar
  47. 47.
    Podoloff DA, Advani RH, Allred C, Benson AB, Brown E, Burstein HJ, Carlson RW, Coleman RE, Czuczman MS, Delbeke D, Edge SB, Ettinger DS, Grannis FW, Hillner BE, Hoffman JM, Keil K, Komaki R, Larson SM, Mankoff DA, Rozenzweig KE, Skibber JM, Yahalom J, Yu JM, Zelenetz AD. NCCN task force report: Positron emission tomography (PET/Computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007;5 (suppl 1): S1–S22. www/nccn.org/professionals/physician_gls/f_guidelines.asp.PubMedGoogle Scholar
  48. 48.
    Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman E, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF.Recommendations for the Use of FDG(fluorine-18, (2-[18 F]Fluoro-2-deoxy-D-glucose) positron emission tomography in oncology. J Nucl Med 2008;49:480–508.CrossRefPubMedGoogle Scholar
  49. 49.
    Abrahamsen A Foss, Andersen A, Nome O, Jacobsen AB, Holte H, Abrahamsen J Foss,Kvaløy S. Long-term risk of second malignancy after treatment of Hodgkin’s disease: the influence of treatment, age and follow-up time. Ann Oncol 2002;13:4786–4791.Google Scholar
  50. 50.
    Macapinlac H. Clinical applications of positron emission tomography/computed tomography treatment planning. Semin Nucl Med 2008;38:137–140.CrossRefPubMedGoogle Scholar
  51. 51.
    Greco C, Rosenzweig K, Cascinic GL, Tamburrini O. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 2007;57:125–134.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Ronald C. Walker
    • 1
  • Laurie B. Jones-Jackson
    • 1
  • Aaron C. Jessop
    • 1
  • Dominique Delbeke
    • 1
  1. 1.Department of Radiology and Radiological SciencesVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations